Nkarta (NKTX) news
Recent news
NKarta expects cash to fund operations into 2029
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases, reported that its cash, cash equivalents, and investments totaled $266.7 million as of March 31, 2026. Based on its current operating…
AInvest Wire · Aug 10, 2026NKarta Inc: TD Cowen initiates coverage with buy rating
TD Cowen analyst Yaron Werber has maintained a Buy rating on Nkarta Inc. (NASDAQ: NKTX), a clinical-stage biopharmaceutical company focused on developing natural killer (NK) cell therapies for autoimmune diseases and cancer. The stock closed at $1.37 on June 23, 2026. Werber, who covers the…
AInvest Wire · Jun 23, 2026ImportantNkarta's stock climbs 28% after FDA approves drug application
AInvest Wire · Oct 17, 2023ImportantNkarta gets FDA clearance of IND application ofr NKX019.
AInvest Wire · Oct 17, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.